Abdominal US every 6 months with or without the use of serum AFP levels is the recommended practice for HCC surveillance in cirrhotic patients worldwide,3, 4, 26, 27 with a sensitivity ranging between 69% and 88% for early‐stage HCC.26 The gene discussed is AFP; the disease is hepatocellular carcinoma.